George LauMing Lung YuGrace WongAlexander ThompsonHasmik GhazinianJin Lin HouTeerha PiratvisuthJi Dong JiaMasashi MizokamiGregory ChengGuo Feng ChenZhen Wen LiuOidov BaatarkhuuAnn Lii ChengWoon Leung NgPatrick LauTony MokJer Ming ChangSaeed HamidA. Kadir DokmeciRino A. GaniDiana A. PayawalPierce ChowJoong Won ParkSimone I. StrasserRosmawaiti MohamedKhin Maung WinTanwandee TawesakShiv Kumar SarinMasao OmataSiriraj HospitalInstitute of Liver and Biliary SciencesBeijing Friendship Hospital, Capital Medical UniversityKaohsiung Medical University Chung-Ho Memorial HospitalNational Taiwan University HospitalMongolian National University of Medical SciencesGeneral Hospital of People's Liberation ArmyUniversitas Indonesia, RSUPN Dr. Cipto MangunkusumoNational Cancer Center, GyeonggiThe Aga Khan University HospitalThe University of TokyoNational Center for Global Health and MedicineUniversity of MacauRoyal Prince Alfred HospitalSingapore General HospitalUniversity of Malaya Medical CentreAnkara ÜniversitesiPrince of Songkla UniversityChinese University of Hong KongSouthern Medical UniversityUnited Christian Hospital Hong KongSt. Vincent's Hospital MelbourneCardinal Santos Medical CenterNork Clinical Hospital of Infectious DiseasesYangon GI and Liver CentreHumanity and Health Clinical Trial CenterYamanashi Central Hospital2022-08-042022-08-042021-10-01Hepatology International. Vol.15, No.5 (2021), 1031-104819360541193605332-s2.0-85113351403https://repository.li.mahidol.ac.th/handle/123456789/77819Background & Aim: Hepatitis B reactivation related to the use of immunosuppressive therapy remains a major cause of liver-related morbidity and mortality in hepatitis B endemic Asia-Pacific region. This clinical practice guidelines aim to assist clinicians in all disciplines involved in the use of immunosuppressive therapy to effectively prevent and manage hepatitis B reactivation. Methods: All publications related to hepatitis B reactivation with the use of immunosuppressive therapy since 1975 were reviewed. Advice from key opinion leaders in member countries/administrative regions of Asian-Pacific Association for the study of the liver was collected and synchronized. Immunosuppressive therapy was risk-stratified according to its reported rate of hepatitis B reactivation. Recommendations: We recommend the necessity to screen all patients for hepatitis B prior to the initiation of immunosuppressive therapy and to administer pre-emptive nucleos(t)ide analogues to those patients with a substantial risk of hepatitis and acute-on-chronic liver failure due to hepatitis B reactivation.Mahidol UniversityMedicineArticleSCOPUS10.1007/s12072-021-10239-x